Quest for the right Drug
מוטיליום MOTILIUM (DOMPERIDONE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
4.2 POSOLOGY AND METHOD OF ADMINISTRATION Motilium should be used at the lowest effective dose for the shortest duration necessary to control nausea and vomiting. It is recommended to take oral Motilium before meals. If taken after meals, absorption of the drug is somewhat delayed. Patients should try to take each dose at the scheduled time. If a scheduled dose is missed, the missed dose should be omitted and the usual dosing schedule resumed. The dose should not be doubled to make up for a missed dose. Usually, the maximum treatment duration should not exceed one week. Adults, and adolescents (12 years of age and older and weighing 35 kg or more One 10 mg tablet up to three times per day, with a maximum dose of 30 mg per day. Hepatic impairment Motilium is contraindicated in moderate or severe hepatic impairment (see section 4.3). Dose modification in mild hepatic impairment is however not needed (see section 5.2). Renal impairment Since the elimination half-life of domperidone is prolonged in severe renal impairment, on repeated administration, the dosing frequency of Motilium should be reduced to once or twice daily depending on the severity of the impairment, and the dose may need to be reduced. Paediatric population Motilium is not indicated for children less than 12 years of age and adolescents weighing less than 35 kg.
שימוש לפי פנקס קופ''ח כללית 1994
Nausea & vomiting and hiccups of various origins such as functional, organic, infections, following radiotherapy or as a result of drug therapy, heartburn secondary to reflux esophagitis
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף
